

## Our approach continued

### 2023 ESG Performance Rating

Our 2023 ESG Performance Rating is **on track**, based on 95% of all performance metrics being met or exceeded.

Assessment of performance against our annual targets has been reviewed, and the overall ESG Performance Rating score has been subject to independent limited assurance for 2023 (see page 55).

Our ESG focus areas	Our six commitments	Our metrics for 2023	Our progress in 2023
<b>Access</b>	Make our products available at value-based prices that are sustainable for our business and implement access strategies that increase the use of our medicines and vaccines to treat and protect underserved people	– Progress towards our 2030 goal of reaching 1.3 billion people in lower income countries with our products	In 2023, we reached 89 million people with our vaccines and antiretrovirals and made 989 million doses of our products available in lower income countries
<b>Global health and health security</b>	Develop novel products and technologies to treat and prevent priority diseases, including pandemic threats	– Progress six Global Health pipeline assets to address priority WHO diseases – Progress 8 R&D projects that address pathogens prioritised by the WHO and CDC as posing the highest level of concern due to drug resistance (critical and/or urgent threats)	Progressed 11 Global Health pipeline assets to address priority WHO diseases including malaria and tuberculosis (TB) Progressed 12 active R&D projects that address pathogens considered critical and/or urgent threats due to drug resistance
<b>Environment</b>	Commit to a net zero, nature positive, healthier planet with ambitious goals set for 2030 and 2045	<b>Climate</b> – Operational emissions reduction (Scope 1 and 2 market-based emissions) <sup>1</sup> – Industrialisation of low-carbon <i>Ventolin</i> initiated, and clinical and non-clinical data available to support regulatory submissions – Percentage of carbon offset volume in project pipeline <sup>2</sup> <b>Water</b> – Average of the percentage of GSK sites and suppliers compliant with wastewater active pharmaceutical ingredient limits and the percentage of sites and suppliers that are compliant with the AMR Industry Alliance Common Antibiotic Manufacturing Framework and discharge limits <b>Waste and materials</b> – Operational waste and material reduction at GSK sites	Reduced our operational emissions by 10% from 2022 Progressed our low-carbon <i>Ventolin</i> programme with the potential to reduce greenhouse gas emissions from the inhaler by 90%. Phase III trials of our next generation, lower-carbon propellant will begin in 2024 and, if successful, regulatory submissions will start in 2025 35% of carbon offset volume in project pipeline Average of 87% of all sites and key suppliers compliant with AMR Alliance and API Wastewater discharge limits. This is down from 94% in 2022, primarily due a scope expansion to include more API suppliers 1% reduction of operational waste and materials at our sites

<sup>1</sup> Scope 1 emissions cover emissions from the direct combustion of fuels on our sites to generate heat and electricity, emissions from our sales fleet vehicles, fugitive losses of propellant during the manufacturing of inhalers and losses from refrigerants used in GSK-owned ancillary equipment and emissions from on-site waste treatment. Scope 2 emissions include any purchased electricity, steam, compressed air and chilled water.

<sup>2</sup> Percentage of 2.1 MtCO<sub>2</sub> offsetting volume in 2030 project pipeline.

## Environment continued

	2020	2021	2022	2023	
<b>Energy</b>					
Natural gas purchased (GWh)	1,873	1,744	1,655	1,567	
<b>Electricity used (GWh)</b>	<b>1,102</b>	<b>1,008</b>	<b>970</b>	<b>958</b>	
Purchased renewable electricity (GWh)	487	631	697	782	(A)
Purchased non-renewable electricity (GWh)	605	372	263	163	
On-site renewably generated electricity (GWh)	19	13	18	17	(A)
Exported electricity (GWh)	9	8	8	4	
Coal (GWh)	0	0	0	0	
Other fossil fuels (GWh)	49	58	81	60	
Renewable heat (GWh)	9	8	13	12	
Purchased heating and cooling (GWh)	52	52	41	39	
<b>Total energy for operations (GWh)</b>	<b>3,085</b>	<b>2,871</b>	<b>2,759</b>	<b>2,636</b>	(A)
% renewable electricity	46%	63%	73%	83%	
<b>Carbon: Scope 1 and 2 emissions</b>					
On-site fuel use (thousands of tonnes CO <sub>2</sub> e)	355	333	320	301	
Sales force vehicles (thousands of tonnes CO <sub>2</sub> e)	60	52	51	46	
Propellant emissions during manufacture of inhalers (thousands of tonnes CO <sub>2</sub> e)	275	237	243	220	
On-site waste or wastewater treatment (thousands of tonnes CO <sub>2</sub> e)	0	0	0	0	
Refrigerant gas losses (thousands of tonnes CO <sub>2</sub> e)	20	11	13	13	
<b>Total Scope 1 emissions (thousands of tonnes CO<sub>2</sub>e)</b>	<b>711</b>	<b>633</b>	<b>626</b>	<b>581</b>	(A)
Electricity (market-based emissions) (thousands of tonnes CO <sub>2</sub> e)	163	125	84	60	
Purchased heating and cooling (thousands of tonnes CO <sub>2</sub> e)	6	6	4	4	
<b>Total Scope 2 market-based emissions (thousands of tonnes CO<sub>2</sub>e)</b>	<b>169</b>	<b>131</b>	<b>88</b>	<b>64</b>	(A)
<b>Total Scope 2 location-based emissions (thousands of tonnes CO<sub>2</sub>e)</b>	<b>309</b>	<b>285</b>	<b>265</b>	<b>240</b>	(A)
<b>Total Scope 1 and 2 market-based emissions (thousands of tonnes CO<sub>2</sub>e)</b>	<b>879</b>	<b>764</b>	<b>715</b>	<b>645</b>	PR (A)
Fermentation/biogenic releases (thousands of tonnes CO <sub>2</sub> e)	27	10	12	12	
<b>Carbon: Scope 3 emissions<sup>1</sup></b>					
Purchased goods and services (thousands of tonnes CO <sub>2</sub> e)	3,267	2,725	2,485	–	
Capital goods (thousands of tonnes CO <sub>2</sub> e)	162	154	161	–	
Fuel and energy-related activities (thousands of tonnes CO <sub>2</sub> e)	89	84	145	–	
Transportation and distribution (upstream) (thousands of tonnes CO <sub>2</sub> e)	267	189	242	–	
Waste generated in operations (thousands of tonnes CO <sub>2</sub> e)	20	64	51	–	
Business travel (thousands of tonnes CO <sub>2</sub> e)	42	50	85	–	
Employee commuting (thousands of tonnes CO <sub>2</sub> e)	37	48	60	–	
Leased assets (upstream) (thousands of tonnes CO <sub>2</sub> e)	0	0	0	–	
Transportation and distribution (downstream) (thousands of tonnes CO <sub>2</sub> e)	135	99	130	–	
Processing of sold products (thousands of tonnes CO <sub>2</sub> e)	0	0	0	–	

PR Metric contributes to our ESG Performance Rating.

(A) Metric's 2023 data has been independently assured.

1 Other than propellant emissions data (which is collected through our internal systems); we will not have an accurate picture of 2023 Scope 3 emissions until later in the year.

## Independent Limited Assurance Report to the Directors of GSK PLC

Independent limited Assurance Report by Deloitte LLP to the Directors of GSK PLC on selected Environmental, Social and Governance (“ESG”) metrics (the “Selected Information”) within the Annual Report and Accounts and the ESG Performance Report for the reporting year ended 31 December 2023.

### Our assurance conclusion

Based on our procedures described in this report, and evidence we have obtained, nothing has come to our attention that causes us to believe that the Selected Information, as presented on page 70 of the Annual Report and Accounts and pages 23-24 of the ESG Performance Report for the year ended 31 December 2023, and as listed below and indicated with an (A) in the Annual Report and Accounts and the ESG Performance Report has not been prepared, in all material respects, in accordance with the Basis of Reporting defined by the directors.

### Scope of our work

GSK PLC has engaged us to perform an independent limited assurance engagement in accordance with International Standard on Assurance Engagements 3000 (Revised) *Assurance Engagements Other than Audits or Reviews of Historical Financial Information* (“ISAE 3000 (Revised)”) and the International Standard on Assurance Engagements 3410 *Assurance engagements on greenhouse gas statements* (ISAE 3410), issued by the International Auditing and Assurance Standards Board (“IAASB”) and our agreed terms of engagement.

The Selected Information in scope of our engagement, as presented on page 70 of the Annual Report and Accounts and pages 23-24 of the ESG Performance Report for the year ended 31 December 2023, and as listed below and indicated with an (A) in the Annual Report and Accounts and ESG Performance Report, is as follows:

Selected Information	Assured Value
Scope 1 emissions (thousand tonnes CO <sub>2</sub> e)	581
Scope 2 emissions – Market Based – (thousand tonnes CO <sub>2</sub> e)	64
Scope 2 emissions – Location Based – (thousand tonnes CO <sub>2</sub> e)	240
Total scope 1 and 2 market-based emissions (thousand tonnes CO <sub>2</sub> e)	645
Total energy for operations (GWh)	2,636
Purchased Renewable electricity (GWh)	782
Onsite renewably generated electricity (GWh)	17
Emissions from use of propellant based inhalers by patients (thousand tonnes CO <sub>2</sub> e)	5,039
Total water use at high water risk sites (million m <sup>3</sup> )	0.3
Total wastewater discharged (million m <sup>3</sup> )	6.2
Total water use (million m <sup>3</sup> )	7.4